Most Recent
Plus500 has lost its bid to permanently stay a class action by investors who lost money trading in highly leveraged financial products, with a court finding that the arbitration clause relied on by the online trader was unfair and void.
Law firm Atanaskovic Hartnell can't appeal a stay of a costs order in its dispute with media mogul Bruce Gordon, with an appeals court saying disputes fuelled by their “mutual animus” should not be encouraged.
Construction PRO
A Sydney developer has successfully challenged a decision which rejected its plans to demolish a 32-room boarding house for the construction of four luxury residences in Paddington, with a judge calling the decision "personal and idiosyncratic".
The Federal Court has dismissed Walter Sofronoff KC’s legal challenge to the ACT Integrity Commission findings that he engaged in corrupt conduct in his inquiry into the prosecution of Bruce Lehrmann.
The High Court has unanimously granted home retailer Bed Bath N’ Table’s appeal of a ruling that retailer House did not engage in misleading and deceptive conduct in setting up its Bed & Bath stores.
A judge has found the ATO knowingly received millions misappropriated by a former Kupang Resources director in order to satisfy a tax debt against him, with a judge skewering the tax office for instituting a “policy of wilful blindness” in pursuit of the debt.
Collapsed supply chain finance company Greensill Bank can't access a copy of a Tokio Marine unit's database, with a judge finding the copy was created for the primary purpose of HWL Ebsworth providing legal advice.
A judge has approved a $110 million settlement in a class action against BHP over the collapse of a tailings dam, and has OK'd fees and commission reducing the sum by 50 per cent, despite concerns the costs were excessive.
A SkyCity shareholder has lost his bid to bring a case against former executives and directors at the ASX-listed casino seeking to recoup a $67 million penalty over breaches of money laundering regulations.
Johnson & Johnson-owned Janssen has secured an injunction against drug maker Juno Pharmaceuticals, halting the release of Juno's generic version of schizophrenia drug Invega Sustenna.